Document Detail


Phase II study of temozolomide and cisplatin as primary treatment prior to radiotherapy in newly diagnosed glioblastoma multiforme patients with measurable disease. A study of the Spanish Medical Neuro-Oncology Group (GENOM).
MedLine Citation:
PMID:  15662978     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
This phase II study evaluates the activity of temozolomide and cisplatin administered before radiation therapy in newly diagnosed glioblastoma multiforme patients, in terms of response, time to progression and survival. PATIENTS AND METHODS: Forty patients with measurable disease after surgery, a Karnofsky status > 60, and Barthel Index > 10 were included. They were treated with three cycles of temozolomide 200 mg/m2/day for 5 days and cisplatin 100 mg/m2 on day 1. Conventional focal radiation therapy to 60 Gy was administered after response evaluation. RESULTS: Three patients were not evaluable for central reviewed response but all 40 were evaluable for toxicity, time to progression and survival. Objective responses by Macdonald criteria on an intent to treat basis were 45% including complete response in three patients (7.5%), and partial response in 15 patients (37.5%). Responses were seen in biopsy-only patients (33.4%) as well as in partial surgery patients (52%). Median survival for all patients was 12.5 months. Biopsy-only patients had a median survival of 12.8 months. Grade 3 to 4 neutropenia was the most important toxicity, and occurred in 37.5% of patients. A delay in 18.2% and a dose reduction in 9.6% of cycles were necessary due to myelosuppression on day 28. Two patients had neutropenic fever resulting in one treatment-related death. Eighty-two percent of patients received radiotherapy. CONCLUSION: This regimen has significant activity, as it induces objective responses even in biopsy-only patients, appearing to improve their median survival. A better combination schedule is needed to improve the toxicity profile.
Authors:
Carmen Balaña; Antonio López-Pousa; Alfonso Berrocal; Ricardo Yaya-Tur; Ana Herrero; Jose-Luis García; Javier Martín-Broto; Manuel Benavides; Miguel Cerdá-Nicolás; Rosa Ballester; Josep Balart; Jaume Capellades
Related Documents :
21377648 - Sentinel node identification using technetium-99m neomannosyl human serum albumin in es...
21455928 - Should possible recurrence of disease contraindicate liver transplantation in patients ...
21431988 - Recurrence and survival in patients undergoing sentinel lymph node biopsy for merkel ce...
21541568 - Impact of tumor cell kinetics on the outcome of induction chemotherapy in oral carcinom...
14671418 - Usefulness of preoperative chemoradiation in locally advanced cervical carcinoma.
18302268 - Differential expression of muc1 and carbohydrate antigens in primary and secondary head...
Publication Detail:
Type:  Clinical Trial; Clinical Trial, Phase II; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't    
Journal Detail:
Title:  Journal of neuro-oncology     Volume:  70     ISSN:  0167-594X     ISO Abbreviation:  J. Neurooncol.     Publication Date:  2004 Dec 
Date Detail:
Created Date:  2005-01-24     Completed Date:  2005-03-03     Revised Date:  2006-11-15    
Medline Journal Info:
Nlm Unique ID:  8309335     Medline TA:  J Neurooncol     Country:  Netherlands    
Other Details:
Languages:  eng     Pagination:  359-69     Citation Subset:  IM    
Affiliation:
Medical Oncology Services, Institut Catala d'Oncologia, Hospital Universitari Germans Trias i Pujol, Badalona, Barcelona, Spain. cbalana@ns.hugtip.scs.es
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Adult
Aged
Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
Brain Neoplasms / mortality*,  therapy*
Cisplatin / administration & dosage
Combined Modality Therapy
Dacarbazine / administration & dosage,  analogs & derivatives*
Female
Glioblastoma / mortality*,  therapy*
Humans
Male
Middle Aged
Radiotherapy
Survival Analysis
Treatment Outcome
Chemical
Reg. No./Substance:
15663-27-1/Cisplatin; 4342-03-4/Dacarbazine; 85622-93-1/temozolomide

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  The relationship between peritumoral brain edema and the expression of vascular endothelial growth f...
Next Document:  Gastric luminal epidermal growth factor is affected by diet.